Sermorelin

Buy Sermorelin Online

Sermorelin is a synthetic growth-hormone-releasing hormone fragment researched for growth hormone secretion, body composition, recovery, and endocrine research.

Product Information

Sermorelin corresponds to GHRH(1-29)-amide, the biologically active N-terminal fragment of human growth hormone-releasing hormone. It stimulates the pituitary to release growth hormone.

How It Works

Sermorelin acts like endogenous GHRH by stimulating the pituitary's growth hormone-releasing pathway. This increases endogenous GH secretion rather than directly supplying growth hormone.

POTENTIAL BENEFITS

1. Growth Hormone Research

Sermorelin has been extensively studied for its ability to stimulate endogenous growth hormone secretion.

2. Growth & Development Research

Clinical research in children with growth-hormone deficiency demonstrated increased growth velocity during sermorelin/GHRH treatment.

3. Body-Composition Research

Because GH influences fat metabolism and lean tissue, sermorelin has attracted interest in research examining changes in body composition.

4. Endocrine Research

Sermorelin provides researchers with a useful model for investigating the relationship between hypothalamic GHRH signaling, pituitary GH release, and IGF-1.

5. Recovery Research

GH signaling is involved in tissue maintenance and repair, making sermorelin relevant to broader research into recovery and regenerative physiology.

Dosage

Historical clinical research in growth-hormone-deficient children used approximately 30 mcg/kg/day subcutaneously. Modern online peptide communities commonly discuss approximately 100–500 mcg/day, but these community protocols should not be confused with the historical clinical dosing used in pediatric studies.

Side Effects

Reported effects include injection-site pain, facial flushing, headache, and changes associated with increased GH/IGF-1 signaling.

References

• Sermorelin: a review of its use in the diagnosis and treatment of growth hormone deficiency. PubMed. PMID: 18031173. PubMed
• Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. PMID: 9141536. PubMed
• Barron JL, et al. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides. 1985;6(3):575-577. PMID: 2866496. PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to access instructions on how to make a payment.

How to Pay